Phase: Phase II
Class: Anti-complement factor D MAb
2020 sales: $1.1 billion
Net present value: $4.5 billion
In an update for investors recently, Roche ($RHHBY) noted that its Phase III for lampalizumab is set to get off the ground sometime in the second half of this year. The pharma giant rolled out promising mid-stage data for age-related macular degeneration close to a year ago. Investigators say that lampalizumab slowed progression of AMD in patients with advanced disease, shrinking the area of geographic atrophy by 20.4% in a specific subpopulation treated monthly with lampalizumab, the "GA" progression rate was decreased by 44% at 18 months, reports Roche. And researchers noted that there were no unexpected side effects from the drug, which could help improve its chances of diversifying its drug portfolio with a new eye drug. Roche obtained the drug from its buyout of Genentech, which in turn acquired the therapy in an acquisition of Tanox in 2007. A success here would help Roche diversify its portfolio, with somewhat less reliance on cancer. And they could build on their success with Lucentis, approved for wet AMD.
Roche's gRED sees promising results in PhII macular degeneration study